•
Sep 30, 2024
Leap Therapeutics Q3 2024 Earnings Report
Leap Therapeutics reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Leap Therapeutics reported a net loss of $18.2 million for the third quarter of 2024, compared to a net loss of $13.7 million for the same period in 2023. Research and development expenses increased to $14.9 million, and the company's cash and cash equivalents totaled $62.8 million as of September 30, 2024.
Completed enrollment in the expanded Part B of the Phase 2 DeFianCe study of DKN-01 in patients with advanced colorectal cancer.
Initial randomized controlled data from the DisTinGuish study and the DeFianCe study is expected in the coming months.
FL-501 is moving into development based on positive preclinical data.
Cash position is expected to fund operations into Q2 2026.